• US Preventive Services Task Force, Kirsten Bibbins-Domingo, David C Grossman, Susan J Curry, Karina W Davidson, John W Epling, GarcíaFrancisco A RFARPima County Department of Health, Tucson, Arizona., Matthew W Gillman, Alex R Kemper, Alex H Krist, Ann E Kurth, C Seth Landefeld, Michael L LeFevre, Carol M Mangione, William R Phillips, Douglas K Owens, Maureen G Phipps, and Michael P Pignone.
• University of California, San Francisco.
• JAMA. 2016 Nov 15; 316 (19): 1997-2007.

ImportanceCardiovascular disease (CVD) is the leading cause of morbidity and mortality in the United States, accounting for 1 of every 3 deaths among adults.ObjectiveTo update the 2008 US Preventive Services Task Force (USPSTF) recommendation on screening for lipid disorders in adults.Evidence ReviewThe USPSTF reviewed the evidence on the benefits and harms of screening for and treatment of dyslipidemia in adults 21 years and older; the benefits and harms of statin use in reducing CVD events and mortality in adults without a history of CVD events; whether the benefits of statin use vary by subgroup, clinical characteristics, or dosage; and the benefits of various treatment strategies in adults 40 years and older without a history of CVD events.Conclusions And RecommendationsThe USPSTF recommends initiating use of low- to moderate-dose statins in adults aged 40 to 75 years without a history of CVD who have 1 or more CVD risk factors (dyslipidemia, diabetes, hypertension, or smoking) and a calculated 10-year CVD event risk of 10% or greater (B recommendation). The USPSTF recommends that clinicians selectively offer low- to moderate-dose statins to adults aged 40 to 75 years without a history of CVD who have 1 or more CVD risk factors and a calculated 10-year CVD event risk of 7.5% to 10% (C recommendation). The USPSTF concludes that the current evidence is insufficient to assess the balance of benefits and harms of initiating statin use in adults 76 years and older (I statement).

32 keywords...

hide…